- Home
- CARM vs LGVN Comparison
CARM vs LGVN Comparison
Compare CARM & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARM
- LGVN
- Stock Information
- Founded
- CARM 2016
- LGVN 2014
- Country
- CARM United States
- LGVN United States
- Employees
- CARM N/A
- LGVN N/A
- Industry
- CARM Biotechnology: Pharmaceutical Preparations
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- CARM Health Care
- LGVN Health Care
- Exchange
- CARM Nasdaq
- LGVN Nasdaq
- Market Cap
- CARM 12.2M
- LGVN 11.5M
- IPO Year
- CARM N/A
- LGVN 2021
- Fundamental
- Price
- CARM $0.24
- LGVN $0.80
- Analyst Decision
- CARM Hold
- LGVN Strong Buy
- Analyst Count
- CARM 5
- LGVN 3
- Target Price
- CARM $0.90
- LGVN $6.33
- AVG Volume (30 Days)
- CARM 447.9K
- LGVN 1.9M
- Earning Date
- CARM 08-07-2025
- LGVN 08-13-2025
- Dividend Yield
- CARM N/A
- LGVN N/A
- EPS Growth
- CARM N/A
- LGVN N/A
- EPS
- CARM N/A
- LGVN N/A
- Revenue
- CARM $10,767,000.00
- LGVN $2,073,000.00
- Revenue This Year
- CARM N/A
- LGVN N/A
- Revenue Next Year
- CARM N/A
- LGVN $51.48
- P/E Ratio
- CARM N/A
- LGVN N/A
- Revenue Growth
- CARM N/A
- LGVN 68.67
- 52 Week Low
- CARM $0.14
- LGVN $0.63
- 52 Week High
- CARM $1.27
- LGVN $2.86
- Technical
- Relative Strength Index (RSI)
- CARM 31.94
- LGVN 33.36
- Support Level
- CARM $0.21
- LGVN $0.73
- Resistance Level
- CARM $0.31
- LGVN $0.87
- Average True Range (ATR)
- CARM 0.03
- LGVN 0.13
- MACD
- CARM -0.00
- LGVN -0.03
- Stochastic Oscillator
- CARM 23.64
- LGVN 17.43
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.